Unterehmen auf Watchlist setzen
Geron
ISIN: US3741631036
WKN: 902213
Curious about what AI knows about Geron? Just one click more
More AI Integrations
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Geron · ISIN: US3741631036 · Business Wire (ID: 20250328965574)
28 März 2025 11:03PM

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm


GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between February 28, 2024 and February 25, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before May 12, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Geron gave investors the false impression that it had reliable information about its projected revenue outlook and anticipated growth. The Company’s optimistic reports of Rytelo’s launch and potential growth were far too optimistic. The Company failed to inform investors that Rytelo lacked necessary patient awareness for the Company to capitalize on what it had claimed was a significant unmet need for the drug. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Geron, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contact

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

Visuelle Wertentwicklung / Kursverlauf · Geron
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
MIC: XNAS
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2025
BusinessWire
Kontakt:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422